PEG-MGF

PEG-MGF is a modified form of Mechano Growth Factor conjugated with polyethylene glycol (PEG) to extend its plasma half-life and enable systemic distribution. Native MGF has a very short half-life (minutes) that limits its utility for in vivo research, particularly when systemic delivery is required.

The PEG moiety (typically 2-5 kDa) increases molecular size, reducing renal clearance and providing steric protection against proteolytic degradation. This extends circulation time from minutes to hours, allowing MGF to distribute throughout the body and reach muscle tissue via the bloodstream.

Research comparing PEG-MGF with native MGF suggests the PEGylated form may have different tissue distribution and receptor interaction profiles. The increased half-life allows study of systemic MGF effects that are difficult to investigate with rapidly cleared native peptide.

However, PEGylation may reduce receptor binding affinity and alter the peptide's biological activity profile. Research applications should consider this trade-off between pharmacokinetic improvement and potential pharmacodynamic changes when selecting between native and PEGylated forms.